128 related articles for article (PubMed ID: 34620629)
41. Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study.
Montero Pérez O; Martinez Benavides J; González Fernandez T; Guerra Prio S; Romero Domínguez R; Mesía Nin R; Clopés Estela A
Expert Rev Clin Pharmacol; 2023; 16(9):877-883. PubMed ID: 37477611
[TBL] [Abstract][Full Text] [Related]
42. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
43. Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.
Armstrong D; Veldhuyzen van Zanten SJ; Barkun AN; Chiba N; Thomson AB; Smyth S; Sinclair P; Chakraborty B; White RJ;
Aliment Pharmacol Ther; 2005 May; 21(10):1189-202. PubMed ID: 15882239
[TBL] [Abstract][Full Text] [Related]
44. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
45. Repeated anaphylactic responses induced by oral challenge with ranitidine.
Walker AI; Werfel S; Kick G; Przybilla B
Acta Derm Venereol; 2010 Mar; 90(2):189. PubMed ID: 20169307
[No Abstract] [Full Text] [Related]
46. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.
Pottegård A; Kristensen KB; Ernst MT; Johansen NB; Quartarolo P; Hallas J
BMJ; 2018 Sep; 362():k3851. PubMed ID: 30209057
[TBL] [Abstract][Full Text] [Related]
47. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.
Robertson DJ; Larsson H; Friis S; Pedersen L; Baron JA; Sørensen HT
Gastroenterology; 2007 Sep; 133(3):755-60. PubMed ID: 17678921
[TBL] [Abstract][Full Text] [Related]
48. Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing.
Park KH; Pai J; Song DG; Sim DW; Park HJ; Lee JH; Jeong KY; Pan CH; Shin I; Park JW
Clin Exp Allergy; 2016 Apr; 46(4):631-9. PubMed ID: 26764898
[TBL] [Abstract][Full Text] [Related]
49. Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients.
Miano TA; Reichert MG; Houle TT; MacGregor DA; Kincaid EH; Bowton DL
Chest; 2009 Aug; 136(2):440-447. PubMed ID: 19318661
[TBL] [Abstract][Full Text] [Related]
50. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group.
Jansen JB; Van Oene JC
Aliment Pharmacol Ther; 1999 Dec; 13(12):1611-20. PubMed ID: 10594396
[TBL] [Abstract][Full Text] [Related]
51. Use of gastric acid-suppressive agents increases the risk of dementia in patients with upper gastrointestinal disease: A population-based retrospective cohort study.
Lin HC; Huang KT; Lin HL; Uang YS; Ho Y; Keller JJ; Wang LH
PLoS One; 2021; 16(3):e0249050. PubMed ID: 33765029
[TBL] [Abstract][Full Text] [Related]
52. Difference between the frequencies of antisecretory drug prescriptions in users of buffered vs. enteric-coated low-dose aspirin therapies.
Hachiken H; Murai A; Wada K; Kuwahara T; Hosomi K; Takada M
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):807-15. PubMed ID: 24040850
[TBL] [Abstract][Full Text] [Related]
53. Association between acid-suppressive drug use and atopic dermatitis in patients with upper gastrointestinal diseases: A population-based retrospective cohort study.
Lin HC; Chen YY; Lin HL; Uang YS; Ho Y; Wang LH
J Clin Pharm Ther; 2021 Jun; 46(3):786-793. PubMed ID: 33403692
[TBL] [Abstract][Full Text] [Related]
54. A cluster randomised, crossover, registry-embedded clinical trial of proton pump inhibitors versus histamine-2 receptor blockers for ulcer prophylaxis therapy in the intensive care unit (PEPTIC study): study protocol.
Young PJ; Bagshaw SM; Forbes A; Nichol A; Wright SE; Bellomo R; Bailey MJ; Beasley RW; Eastwood GM; Festa M; Gattas D; van Haren F; Litton E; Mouncey PR; Navarra L; Pilcher D; Mackle DM; McArthur CJ; McGuinness SP; Saxena MK; Webb S; Rowan KM;
Crit Care Resusc; 2018 Sep; 20(3):182-189. PubMed ID: 30153780
[TBL] [Abstract][Full Text] [Related]
55. Exposure to oral bisphosphonates and risk of gastrointestinal cancer.
Choi D; Choi S; Chang J; Park SM
Osteoporos Int; 2020 Apr; 31(4):775-782. PubMed ID: 32034451
[TBL] [Abstract][Full Text] [Related]
56. Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.
Peura DA; Freston JW; Haber MM; Kovacs TO; Hunt B; Atkinson S
Dig Dis Sci; 2009 May; 54(5):955-63. PubMed ID: 18726153
[TBL] [Abstract][Full Text] [Related]
57. Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients.
O'Keefe GE; Gentilello LM; Maier RV
Ann Surg; 1998 Jan; 227(1):120-5. PubMed ID: 9445119
[TBL] [Abstract][Full Text] [Related]
58. Possible cholestatic injury from ranitidine with a review of the literature.
Ramrakhiani S; Brunt EM; Bacon BR
Am J Gastroenterol; 1998 May; 93(5):822-6. PubMed ID: 9625136
[TBL] [Abstract][Full Text] [Related]
59. Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial.
Florian J; Matta MK; DePalma R; Gershuny V; Patel V; Hsiao CH; Zusterzeel R; Rouse R; Prentice K; Nalepinski CG; Kim I; Yi S; Zhao L; Yoon M; Selaya S; Keire D; Korvick J; Strauss DG
JAMA; 2021 Jul; 326(3):240-249. PubMed ID: 34180947
[TBL] [Abstract][Full Text] [Related]
60. Severe anaphylactoid reaction to ranitidine in a parturient with subsequent fetal distress.
Kaneko K; Maruta H
J Anesth; 2003; 17(3):199-200. PubMed ID: 12911210
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
